Systemic interferon alpha 2b treatment in Behçet's syndrome

Area of Science:

• Rheumatology
• Immunology
• Dermatology

Background:

• Behçet's syndrome is a chronic inflammatory disorder affecting multiple systems.
• Mucocutaneous and joint symptoms are common and can significantly impact patient quality of life.

Purpose of the Study:

• To evaluate the efficacy of systemic interferon alpha 2b (IFN alpha 2b) in managing the mucocutaneous and joint symptoms of Behçet's syndrome.
• To assess the impact of IFN alpha 2b on arthritis attacks, lesion counts, and inflammatory markers.

Main Methods:

• A 48-week, open-label, self-controlled trial involving 20 Behçet's syndrome patients.
• Treatment involved phased administration of IFN alpha 2b (5 million units three times weekly, then once weekly).
• Patient outcomes were monitored during pretreatment, treatment, and posttreatment phases.

Main Results:

• IFN alpha 2b significantly decreased the number and duration of arthritis attacks (p < 0.05).
• A significant reduction in erythrocyte sedimentation rate (ESR) was observed (p < 0.001).
• While mucocutaneous lesion counts decreased, this change was not statistically significant.

Conclusions:

• Systemic interferon alpha 2b shows potential efficacy in treating the arthritis associated with Behçet's syndrome.
• Further research is warranted to confirm these findings and explore optimal treatment protocols.